Suven Life Sciences, a biopharmaceutical company, has registered satisfactory performance during the quarter ended June 2014 and its net profit surged by 16.7 per cent to Rs. 34.74 crore from Rs. 29.77 crore in the corresponding period of last year. Its net sales also moved up by 30.2 per cent to Rs. 141.53 crore from Rs. 108.67 crore. EPS worked out to Rs. 2.97 as against Rs. 2.55 in the last period. Its EBDITA improved by 27.7 per cent to Rs. 58.96 crore from Rs. 46.18 crore. Its R&D expenditure increased to Rs. 8.90 crore during the quarter under review and this worked out to 6.3 per cent of revenue.
The company's sales from CRAMS increased to Rs. 138.95 crore from Rs. 106.89 crore, a growth of 30 per cent and that from drug discovery development support services (DDDSS) improved to Rs. 2.58 crore from Rs. 1.78 crore.
The company has 666 product patents for 18 inventions and 36 process patents. SUVN D-4010 and SUVN G-3031 are undergoing IND enabling toxicological studies in USA in preparation for phase I clinical trial. SUVN 502 is undergoing phase 1b clinical trials in USA in preparation for phase 2a (POC) study on patients in USA.
Suven has 386 scientists engaged in its R&D activities and currently 13 molecules are in NCE research pipeline. It has undertaken 650 CRAMS projects since inception and its 80 per cent revenue is coming from US and Europe.